Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human antigen R (HuR), also known as ELAV-like protein 1 (ELAVL1), is a ubiquitously expressed RNA-binding protein that plays a central role in the post-transcriptional regulation of gene expression. It binds to AU-rich elements (AREs) in the 3′ untranslated regions (UTRs) of target mRNAs, stabilizing them and influencing their translation into proteins. HuR is involved in several key cellular processes, including embryonic development, stress responses, immune system regulation, cell cycle control, and apoptosis. It has been implicated in pathological conditions such as tumorigenesis, inflammation, cardiac hypertrophy/fibrosis, neurodegeneration, and liver disease. Given its central role, HuR is considered a promising therapeutic target for cancer treatment and other diseases characterized by aberrant post-transcriptional gene regulation.
Disruption of HuR-RNA interactions (potential therapeutic strategy)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Antigen R (None).